Skip to content

Study · Non-randomized trial · n = 52 · 2010

8 results

Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study.

Borggrefe J, Graeff C, Nickelsen TN, Marin F, Glüer CC

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Mar 2010Cited by 85 (Europe PMC)

PMID19778182 (opens in a new tab)DOI10.1359/jbmr.090820 (opens in a new tab)PepBankPUB-19778182
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, teriparatide increased femoral neck areal BMD by 4.0% versus baseline.

    In plain wordsIn women with severe osteoporosis, teriparatide increased femoral neck bone density measured by area compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral neck areal BMD
    Study

    n = 52

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Measurements

    Areal BMD change
    4%
    24 months versus baseline

    Source sentences

    Summary
    After 24 months of TPTD treatment, areal and volumetric FN BMD increased significantly by 4.0% and 3.0%, respectively, compared with baseline.
    1 context sentence
    Summary · context
    Fifty-two postmenopausal women with severe osteoporosis were analyzed.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, teriparatide increased femoral neck volumetric BMD by 3.0% versus baseline.

    In plain wordsIn women with severe osteoporosis, teriparatide increased femoral neck bone density measured by volume compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral neck volumetric BMD
    Study

    n = 52

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Measurements

    Volumetric BMD change
    3%
    24 months versus baseline

    Source sentences

    Summary
    After 24 months of TPTD treatment, areal and volumetric FN BMD increased significantly by 4.0% and 3.0%, respectively, compared with baseline.
    1 context sentence
    Summary · context
    Fifty-two postmenopausal women with severe osteoporosis were analyzed.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, cortical volumetric BMD decreased in locations that did not adversely affect minimum bending strength indicators.

    In plain wordsIn women with osteoporosis, cortical bone density decreased versus baseline in locations that did not adversely affect minimum bending strength indicators.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCortical volumetric BMD
    Study

    n = 52

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Decreases in cortical volumetric BMD occurred in locations not adversely affecting minimum bending strength indicators.
    1 context sentence
    Summary · context
    Fifty-two postmenopausal women with severe osteoporosis were analyzed.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, cortical cross-sectional area increased by 4.3% during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, cortical bone area increased compared with baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCortical cross-sectional area
    Study

    n = 52

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Measurements

    Cortical CSA change
    4.3%
    study duration

    Source sentences

    Summary
    Cortical CSA increased by 4.3%, whereas total CSA remained unchanged over the study duration, indicating that endosteal but no periosteal growth was observed.
    1 context sentence
    Summary · context
    Fifty-two postmenopausal women with severe osteoporosis were analyzed.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, total cross-sectional area remained unchanged during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, total bone area remained unchanged compared with baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTotal cross-sectional area
    Study

    n = 52

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Cortical CSA increased by 4.3%, whereas total CSA remained unchanged over the study duration, indicating that endosteal but no periosteal growth was observed.
    1 context sentence
    Summary · context
    Fifty-two postmenopausal women with severe osteoporosis were analyzed.
  6. 06HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, buckling strength parameters did not change after 6 and 12 months of teriparatide.

    In plain wordsIn women with severe osteoporosis, buckling strength measures did not change compared with baseline at the earlier assessments.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBuckling strength parameters at earlier assessments
    Study

    n = 52

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 and 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Strength parameters for buckling did not change at 6 and 12 months but improved significantly at 24 months.
    1 context sentence
    Summary · context
    Fifty-two postmenopausal women with severe osteoporosis were analyzed.
  7. 07HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, buckling strength parameters improved significantly after 24 months of teriparatide.

    In plain wordsIn women with severe osteoporosis, buckling strength measures improved compared with baseline after teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBuckling strength parameters at final assessment
    Study

    n = 52

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Strength parameters for buckling did not change at 6 and 12 months but improved significantly at 24 months.
    1 context sentence
    Summary · context
    Fifty-two postmenopausal women with severe osteoporosis were analyzed.
  8. 08HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, bending strength measures showed a trend toward improvement during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, bending strength measures tended to improve compared with baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBending strength
    Study

    n = 52

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Measures of bending strength showed a trend toward improvement.
    1 context sentence
    Summary · context
    Fifty-two postmenopausal women with severe osteoporosis were analyzed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.